A great deal of concern exists with respect to the ownership of genetically modified organisms by corporate entities. These entities in many cases hold patents to the genetic information of said organisms, raising questions about the ability to own and legislate the building blocks of life. That control rests in the corporate sector also opens many questions about ethics, economic incentives and other practices.
